Drug Profile
Alisertib - Takeda Oncology
Alternative Names: Alisertib sodium; Alsertib; MLN 8237; MLN8237-004Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Fox Chase Cancer Center; M. D. Anderson Cancer Center; Massachusetts General Hospital; Mayo Clinic; Millennium; National Cancer Institute (USA); Northwestern University; Ohio State University Comprehensive Cancer Center; Puma Biotechnology; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
- Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Halogenated hydrocarbons; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Peripheral T-cell lymphoma
- Phase II Acute myeloid leukaemia; Breast cancer; Small cell lung cancer
- Phase I/II Squamous cell cancer
- Discontinued B-cell lymphoma; Brain cancer; Burkitt's lymphoma; Cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gynaecological cancer; HER2 negative breast cancer; Lymphoma; Mesothelioma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours
Most Recent Events
- 20 Mar 2024 US FDA announces allowance to proceed with the phase II ALISCA-Breast1 trial in HER2-negative breast cancer, under IND application
- 20 Mar 2024 Puma Biotechnology plans a phase III trial in HER2-negative breast cancer (Metastatic disease, Combination therapy)
- 20 Mar 2024 Puma Biotechnology plans the phase II ALISCA-Breast1 trial in HER2-negative breast cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in 2H of 2024 (PO)